Data supporting "A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of Electroporated HIV DNA with or without Interleukin 12 in Prime-Boost Combinations with an Ad35 HIV Vaccine in Healthy HIV-Seronegative African Adults"
Author(s)
Type
Dataset
Abstract
Data supporting Mpendo J, Mutua G, Nyombayire J, Ingabire R, Nanvubya A, Anzala O, et al. (2015) A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of Electroporated HIV DNA with or without Interleukin 12 in Prime-Boost Combinations with an Ad35 HIV Vaccine in Healthy HIV-Seronegative African Adults. PLoS ONE 10(8): e0134287. doi:10.1371/journal.pone.0134287
Date Issued
2015-08-07
Citation
2015
Is Referenced By
Subjects
Enzyme-linked immunoassays
T cells
HIV
Vaccines
Cytotoxic T cells
Antibodies
Vaccination and immunization
DNA vaccination
Data Access
The authors confirm that, for approved reasons, some access restrictions apply to the data underlying the findings. The original B004 study set – is available on request from IAVI’s data analysis and coordinating center housed at The EMMES Corporation, Rockville, MD at 'iavitrials@emmes.com.' Data will be available from The EMMES Corporation, for researchers who meet the criteria for access to confidential data. The requests will be screened by IAVI to ensure that the data will be used in accordance with participants' written informed consent. Therefore, the data is not available in a public repository.